Alterity Therapeutics' 1-for-50 Reverse Stock Split Becomes Effective
ATHE sits 51% above its 52-week low of $2.66.
Summary
Alterity Therapeutics has completed its 1-for-50 reverse stock split, consolidating its share capital and adjusting the per-share price accordingly.
Key Events · Corporate Governance and Compliance · ATHE
-
Reverse Stock Split Effective
The company's 1-for-50 reverse stock split, approved by shareholders on May 29, 2026, is now effective.
-
Temporary Trading Code
Shares will trade under the temporary ASX code "ATHDA" until June 11, 2026, with normal trading resuming on June 12 under "ATH".
-
Share Capital Consolidation
Shareholder holdings have been reduced by a 1-for-50 ratio, with fractional entitlements rounded up.
Analysis · ATHE · Life Sciences
This filing confirms the execution of the 1-for-50 reverse stock split, previously approved by shareholders on May 29, 2026. This action significantly reduces the number of outstanding shares and proportionally increases the per-share price, aiming to meet exchange listing requirements and potentially attract broader institutional investment. While a reverse split doesn't change the company's overall market capitalization, it can impact investor perception and liquidity.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.6% of the 1216 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATHE was trading at $4.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $61.2M. The 52-week trading range was $2.66 to $7.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.